VRK2 and pancreatic adenocarcinoma: Consistently with the findings in these DEPs, we found that PKM-ENO1 showed a consistent poor prognosis value (p < 0.05) in pancreatic adenocarcinoma and HNSC/ESCC, whereas VRK2-TP63 showed a poor prognostic value (p < 0.05) in pancreatic adenocarcinoma and a good prognostic value in ESCC/LUSC (Supplementary Fig. 6c).